{"id":"diluent-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diluents for insulin are sterile solutions used to dilute concentrated insulin preparations to achieve desired dosing concentrations or to improve stability and administration characteristics. This formulation from University Health Network appears to be a specialized diluent vehicle for insulin delivery, potentially optimizing bioavailability or patient convenience in Phase 3 development.","oneSentence":"A diluent formulation designed to facilitate the preparation and administration of insulin by reducing concentration or adjusting osmolality.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:31.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT05006599","phase":"PHASE2","title":"SNIFF - 3-Week Aptar CPS Device","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-05","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset","enrollment":""},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT06180824","phase":"NA","title":"Efficacy and Safety Between Different Dilution of Insulin","status":"RECRUITING","sponsor":"Universiti Sains Malaysia","startDate":"2024-01-09","conditions":"Hyperglycemia","enrollment":74},{"nctId":"NCT06144255","phase":"PHASE1","title":"Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)","status":"COMPLETED","sponsor":"Florian Schmitzberger","startDate":"2023-11-17","conditions":"Healthy","enrollment":6},{"nctId":"NCT03915613","phase":"PHASE1, PHASE2","title":"Brain Insulin Resistance in Mood Disorders","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-10-06","conditions":"Major Depressive Disorder, Bipolar Disorder, Anhedonia","enrollment":150},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT02988401","phase":"PHASE1, PHASE2","title":"Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-12-01","conditions":"Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive","enrollment":105},{"nctId":"NCT03383822","phase":"PHASE1, PHASE2","title":"Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-09-08","conditions":"Insulin Resistance","enrollment":7},{"nctId":"NCT02382536","phase":"","title":"Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2014-08","conditions":"Diabetes","enrollment":60},{"nctId":"NCT02810015","phase":"PHASE2","title":"Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2016-07","conditions":"Temporo-Myofascial Disorder","enrollment":40},{"nctId":"NCT02131948","phase":"PHASE1","title":"Regulation of Endogenous Glucose Production by Brain Insulin Action","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-11","conditions":"Insulin Resistance, Diabetes","enrollment":8},{"nctId":"NCT00570050","phase":"PHASE3","title":"Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":35},{"nctId":"NCT00673621","phase":"PHASE1","title":"A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2008-05","conditions":"Asthma, Diabetes Mellitus","enrollment":30},{"nctId":"NCT00314314","phase":"PHASE3","title":"The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":112,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diluent / Insulin","genericName":"Diluent / Insulin","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A diluent formulation designed to facilitate the preparation and administration of insulin by reducing concentration or adjusting osmolality. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}